This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Heinemann, V.
Right arrow Articles by Wilmanns, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heinemann, V.
Right arrow Articles by Wilmanns, W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 06 1997, 1275-1280, Vol 41, No. 6
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients

V Heinemann, D Bosse, U Jehn, B Kahny, K Wachholz, A Debus, P Scholz, HJ Kolb and W Wilmanns
Klinikum Grosshadern, III Medical Clinic, University of Munich, Germany.

The liposomal formulation of amphotericin B (AmBisome) greatly reduces the acute and chronic side effects of the parent drug. The present study describes the pharmacokinetic characteristics of AmBisome applied to 10 patients at a dose of 2.8 to 3.0 mg/kg of body weight and compares them to the pharmacokinetics observed in 6 patients treated with amphotericin B deoxycholate at the standard dose of 1.0 mg/kg. Interpatient variabilities of amphotericin B peak concentrations (Cmax) and areas under concentration-time curves (AUC) were 8- to 10-fold greater for patients treated with AmBisome than for patients treated with amphotericin B deoxycholate. At the threefold greater dose of AmBisome, median Cmaxs were 8.4-fold higher (14.4 versus 1.7 microg/ml) and median AUCs exceeded those observed with amphotericin B deoxycholate by 9-fold. This was in part explained by a 5.7-fold lower volume of distribution (0.42 liters/kg) in AmBisome-treated patients. The elimination of amphotericin B from serum was biphasic for both formulations. However, the apparent half-life of elimination was twofold shorter for AmBisome (P = 0.03). Neither hemodialysis nor hemofiltration had a significant impact on AmBisome pharmacokinetics as analyzed in one patient. In conclusion, the liposomal formulation of amphotericin B significantly (P = 0.001) reduces the volume of drug distribution, thereby allowing for greater drug concentrations in serum. The low toxicity of AmBisome therefore cannot readily be explained by its serum pharmacokinetics.


This article has been cited by other articles:

  • Luo, L-C., Cheng, D-Y., Zhu, H., Shu, X., Chen, W-B. (2009). Inflammatory pseudotumoural endotracheal mucormycosis with cartilage damage. ERR 18: 186-189 [Abstract] [Full Text]  
  • Bedikian, A. Y., Vardeleon, A., Smith, T., Campbell, S., Namdari, R. (2006). Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients.. J Clin Pharmacol 46: 727-737 [Abstract] [Full Text]  
  • Brime, B., Frutos, P., Bringas, P., Nieto, A., Ballesteros, M. P., Frutos, G. (2003). Comparative pharmacokinetics and safety of a novel lyophilized amphotericin B lecithin-based oil-water microemulsion and amphotericin B deoxycholate in animal models. J Antimicrob Chemother 52: 103-109 [Abstract] [Full Text]  
  • Onda, M., Inoue, Y., Kawabata, M., Mita, T. (2003). Susceptibilities of Phospholipid Vesicles Containing Different Sterols to Amphotericin B-Loaded Lysophosphatidylcholine Micelles. J Biochem 134: 121-128 [Abstract] [Full Text]  
  • Bellmann, R., Egger, P., Gritsch, W., Bellmann-Weiler, R., Joannidis, M., Kaneider, N., Dunzendorfer, S., Wiedermann, C. J. (2003). Amphotericin B lipid formulations in critically ill patients on continuous veno-venous haemofiltration. J Antimicrob Chemother 51: 671-681 [Abstract] [Full Text]  
  • Bekersky, I., Fielding, R. M., Dressler, D. E., Lee, J. W., Buell, D. N., Walsh, T. J. (2002). Pharmacokinetics, Excretion, and Mass Balance of Liposomal Amphotericin B (AmBisome) and Amphotericin B Deoxycholate in Humans. Antimicrob. Agents Chemother. 46: 828-833 [Abstract] [Full Text]  
  • Louie, A., Kaw, P., Banerjee, P., Liu, W., Chen, G., Miller, M. H. (2001). Impact of the Order of Initiation of Fluconazole and Amphotericin B in Sequential or Combination Therapy on Killing of Candida albicans In Vitro and in a Rabbit Model of Endocarditis and Pyelonephritis. Antimicrob. Agents Chemother. 45: 485-494 [Abstract] [Full Text]  
  • Louie, A., Liu, W., Miller, D. A., Sucke, A. C., Liu, Q.-F., Drusano, G. L., Mayers, M., Miller, M. H. (1999). Efficacies of High-Dose Fluconazole plus Amphotericin B and High-Dose Fluconazole plus 5-Fluorocytosine versus Amphotericin B, Fluconazole, and 5-Fluorocytosine Monotherapies in Treatment of Experimental Endocarditis, Endophthalmitis, and Pyelonephritis Due to Candida albicans. Antimicrob. Agents Chemother. 43: 2831-2840 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»